NP
Nagaraju Peddapasupula
About Nagaraju Peddapasupula
Data last updated:
Nagaraju Peddapasupula is a Director at Renwin Life Sciences Private Limited (since 2019). The companies operate in Business Services and Pharma. Earlier, Nagaraju Peddapasupula was a Director at Innozen Healthcare Private Limited (2020–2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Renwin Life Sciences Private Limited U74999MH2019PTC319615 | Director | 15 Jan 2019 | 2019 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Innozen Healthcare Private Limited U24230TG2020PTC140140 | Director | 18 Apr 2020 | 2020 | ₹41.9 Lakh (FY 2023) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Nagaraju Peddapasupula
| Name | DIN | Company | Designation |
|---|---|---|---|
| Vardhi Jayshanker | 08332142 | Renwin Life Sciences Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Nagaraju Peddapasupula
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nagaraju Peddapasupula
Nagaraju Peddapasupula currently holds 1 directorship: Renwin Life Sciences Private Limited (Director, since 15 Jan 2019).
Nagaraju Peddapasupula was first appointed on 15 Jan 2019 as Director at Renwin Life Sciences Private Limited. The most recent appointment on record is 18 Apr 2020 at Innozen Healthcare Private Limited.
Nagaraju Peddapasupula held 1 earlier board appointment: Innozen Healthcare Private Limited (Director, 18 Apr 2020 to 24 Jan 2024).
The current boards of Nagaraju Peddapasupula's companies include Vardhi Jayshanker (Renwin Life Sciences Private Limited).